Atara Biotherapeutics Inc... (ATRA)
7.46
-0.31 (-3.99%)
At close: Feb 20, 2025, 3:59 PM
7.52
0.80%
After-hours: Feb 20, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 6.95 |
| Market Cap | 42.97M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -25.32 |
| PE Ratio (ttm) | -0.29 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 7.8 |
| Volume | 75,385 |
| Avg. Volume (20D) | 214,913 |
| Open | 7.82 |
| Previous Close | 7.77 |
| Day's Range | 7.41 - 7.82 |
| 52-Week Range | 5.40 - 23.45 |
| Beta | undefined |
About ATRA
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company i...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 16, 2014
Employees 159
Stock Exchange NASDAQ
Ticker Symbol ATRA
Website https://www.atarabio.com
Analyst Forecast
According to 6 analyst ratings, the average rating for ATRA stock is "Buy." The 12-month stock price forecast is $17.5, which is an increase of 134.58% from the latest price.
Buy 50.00%
Hold 33.33%
Sell 16.67%
Next Earnings Release
Atara Biotherapeutics Inc. is scheduled to release its earnings on Mar 27, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+22.19%
Atara Biotherapeutics shares are trading higher af...
Unlock content with
Pro Subscription
5 months ago
Atara Biotherapeutics shares are trading higher. The company announced a $36 million registered direct offering of 758900 shares at $8.25 per share.
